Cerevance Announces Positive Results for Solengepras in Reducing "Off" Time and Improving Sleep

The biotechnology company Cerevance recently presented detailed Phase 2 clinical trial results at the AD/PD™ 2026 International Conference, offering a clearer picture of how their lead compound, solengepras, could transform daily life for people with the condition. Unlike traditional treatments that rely on replacing dopamine, solengepras works through a novel mechanism: it is a first-in-class GPR6 inhibitor that targets the "indirect pathway" of the brain to restore balance and improve movement. The trial data provides concrete evidence of the treatment's efficacy, particularly for those experiencing motor fluctuations. Key findings include: Significant Reduction in "Off" Time: In a study of people experiencing motor fluctuations as an add-on to levodopa, those taking a 150 mg daily dose saw a statistically significant reduction of 1.3 hours in average daily "off" time after just 27 days. Benefits for Frequent Fluctuations: For a subgroup of participants who started the trial with three or more hours of "off" time per day, the results were even more pronounced, with a 1.78-hour reduction compared to the placebo group. Improved "Good On" Time: These reductions translated into a meaningful increase in "good on" time—periods when symptoms are well-controlled without the interference of troublesome involuntary movements (dyskinesia). Addressing Sleep and Daytime Fatigue: Beyond movement, the ASCEND trial results highlighted significant improvements in non-motor symptoms. The largest standardised improvement was observed in sleep-related disturbances. Additionally, participants showed a trend toward reduced daytime sleepiness, a common and frustrating side effect of many current dopaminergic medications. One of the most encouraging aspects of the trial was the safety profile. Solengepras was generally well-tolerated, with a low rate of adverse events. The most common side effects, such as mild headaches or nausea, were transient, and notably, the treatment did not increase the risk of dyskinesia—a frequent complication of long-term levodopa use. Cerevance identified this breakthrough target using their proprietary NETSseq platform, which allows them to map the genetics of specific brain cells with incredible precision. By focusing on GPR6, solengepras aims to provide a non-dopaminergic alternative that addresses both motor and non-motor symptoms simultaneously. With these positive Phase 2 results, the treatment has now moved into a global Phase 3 trial called ARISE. This larger study is currently enrolling approximately 330 participants to further evaluate the long-term efficacy and safety of solengepras as an adjunctive therapy. If successful, this once-daily oral pill could offer a more stable and predictable way to manage the condition.